Citius Oncology, Inc. (CTOR) vs Organigram Global Inc. (OGI)

Citius Oncology, Inc. and Organigram Global Inc. are both Drug Manufacturers Specialty & Generic companies. Organigram Global Inc. is the larger, with a market value of $155.1M against $97.6M — 1.6× the size. Citius Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; Organigram Global Inc. trades at 2.4×. Organigram Global Inc. has the higher net margin (28.4% vs 0.00%) and the higher return on invested capital (−1.53% vs −67.2%). Across the 13 metrics below, Organigram Global Inc. leads on 11 and Citius Oncology, Inc. on 2.

Valuation

Metric CTOR OGI Drug Manufacturers Specialty & Generic median
P/E n/m 2.37 20.14
P/S n/m 0.67 2.25
P/B 2.81 0.42 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m 16.79 12.29
EV/Sales n/m 0.70 2.56
Earnings yield (44.76%) 42.26% (2.99%)
Free cash flow yield (28.37%) (14.22%) 0.00%

Profitability

Metric CTOR OGI Drug Manufacturers Specialty & Generic median
Gross margin — 36.47% 53.94%
Operating margin 0.00% (3.91%) 0.00%
Net margin 0.00% 28.44% 0.00%
Free cash flow margin 0.00% (9.46%) 0.00%
Return on equity (126.58%) 20.20% (0.40%)
Return on assets (45.20%) 12.70% (3.32%)
Return on invested capital (67.15%) (1.53%) 0.00%

Growth

Metric CTOR OGI Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 39.51% 10.01%
EPS growth (last fiscal year) (9.68%) 60.00% —
Revenue growth, 5-year CAGR — 24.30% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CTOR OGI Drug Manufacturers Specialty & Generic median
Debt to equity 0.50 0.04 0.05
Current ratio 0.73 2.61 2.31
Net debt to EBITDA (0.40) (31.56) 0.85

Dividend

Metric CTOR OGI Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio — 0.00 0.00

Size

Metric CTOR OGI Drug Manufacturers Specialty & Generic median
Market cap 97.63m 155.11m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack